27613550|t|Urinary pH Levels are Strongly Associated with Bladder Recurrence After Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients with a Smoking History
27613550|a|Aromatic amines, well-known bladder carcinogens, derived from cigarette smoke are activated by acidic urine. We herein determined whether urinary pH levels are associated with bladder recurrence in upper tract urothelial carcinoma patients with a positive smoking history. A total of 256 upper tract urothelial carcinoma patients who were surgically treated at our institution between 1990 and 2013 were included. Urinary pH levels were defined as the median of at least two consecutive measurements within 1 month of surgery. Ninety-six patients (37.5 %) had pH <5.5 and 160 (62.5 %) had pH ≥5.5, and urinary pH levels were identified as one of the significant predictors for bladder recurrence in univariate but not multivariate Cox regression analysis in overall. In patients with a positive smoking history among those without a history of bladder tumor (N = 110), the 5-year bladder recurrence - free survival rate was 52.5 % in patients with pH ≥5.5, which was significantly higher than that in those with pH <5.5 (25.9 %, p = 0.032). In the multivariate analysis, urinary pH <5.5 (p = 0.022, HR; 1.86) was independently associated with bladder recurrence. No significant difference for bladder recurrence was observed between these two groups in patients with no smoking history among them. Urinary pH <5.5 is associated with an increased risk of bladder recurrence in upper tract urothelial carcinoma patients with a positive smoking history among those without a history of bladder tumor. Modifications to pH for urine alkalization may prevent bladder recurrence.
27613550	0	7	Urinary	T031	C0042036
27613550	8	17	pH Levels	T034	C1304686
27613550	31	46	Associated with	T080	C0332281
27613550	47	54	Bladder	T023	C0005682
27613550	55	65	Recurrence	T046	C2825055
27613550	72	90	Nephroureterectomy	T061	C0027732
27613550	94	126	Upper Tract Urothelial Carcinoma	T191	C2145472
27613550	127	135	Patients	T101	C0030705
27613550	143	158	Smoking History	T033	C1519384
27613550	159	174	Aromatic amines	T109	C0682958
27613550	187	194	bladder	T023	C0005682
27613550	195	206	carcinogens	T131	C0007090
27613550	221	236	cigarette smoke	T131	C0239059
27613550	241	250	activated	T052	C1879547
27613550	254	266	acidic urine	T031	C0042036
27613550	297	304	urinary	T031	C0042036
27613550	305	314	pH levels	T034	C1304686
27613550	319	334	associated with	T080	C0332281
27613550	335	342	bladder	T023	C0005682
27613550	343	353	recurrence	T046	C2825055
27613550	357	389	upper tract urothelial carcinoma	T191	C2145472
27613550	390	398	patients	T101	C0030705
27613550	406	414	positive	T033	C1514241
27613550	415	430	smoking history	T033	C1519384
27613550	447	479	upper tract urothelial carcinoma	T191	C2145472
27613550	480	488	patients	T101	C0030705
27613550	498	508	surgically	T061	C0543467
27613550	509	516	treated	T169	C1522326
27613550	524	535	institution	T093	C2607850
27613550	573	580	Urinary	T031	C0042036
27613550	581	590	pH levels	T034	C1304686
27613550	611	617	median	T081	C0876920
27613550	634	645	consecutive	T080	C1707491
27613550	646	658	measurements	T169	C0242485
27613550	677	684	surgery	T061	C0543467
27613550	697	705	patients	T101	C0030705
27613550	719	721	pH	T081	C0020283
27613550	748	750	pH	T081	C0020283
27613550	761	768	urinary	T031	C0042036
27613550	769	778	pH levels	T034	C1304686
27613550	784	794	identified	T080	C0205396
27613550	821	831	predictors	T078	C2698872
27613550	836	843	bladder	T023	C0005682
27613550	844	854	recurrence	T046	C2825055
27613550	858	868	univariate	T062	C0683962
27613550	877	889	multivariate	T081	C0026777
27613550	890	913	Cox regression analysis	T170	C0034980
27613550	929	937	patients	T101	C0030705
27613550	945	953	positive	T033	C1514241
27613550	954	969	smoking history	T033	C1519384
27613550	992	999	history	T033	C1519384
27613550	1003	1016	bladder tumor	T191	C0005695
27613550	1039	1046	bladder	T023	C0005682
27613550	1047	1057	recurrence	T046	C2825055
27613550	1060	1073	free survival	T081	C0242793
27613550	1074	1078	rate	T081	C2986537
27613550	1093	1101	patients	T101	C0030705
27613550	1107	1109	pH	T081	C0020283
27613550	1126	1146	significantly higher	T081	C4055637
27613550	1171	1173	pH	T081	C0020283
27613550	1207	1228	multivariate analysis	T081	C0026777
27613550	1230	1237	urinary	T031	C0042036
27613550	1238	1240	pH	T081	C0020283
27613550	1258	1260	HR	T081	C2985465
27613550	1286	1301	associated with	T080	C0332281
27613550	1302	1309	bladder	T023	C0005682
27613550	1310	1320	recurrence	T046	C2825055
27613550	1322	1347	No significant difference	T033	C3842396
27613550	1352	1359	bladder	T023	C0005682
27613550	1360	1370	recurrence	T046	C2825055
27613550	1402	1408	groups	T078	C0441833
27613550	1412	1420	patients	T101	C0030705
27613550	1426	1428	no	T033	C1513916
27613550	1429	1444	smoking history	T033	C1519384
27613550	1457	1464	Urinary	T031	C0042036
27613550	1465	1467	pH	T081	C0020283
27613550	1476	1491	associated with	T080	C0332281
27613550	1495	1504	increased	T081	C0205217
27613550	1505	1509	risk	T078	C0035647
27613550	1513	1520	bladder	T023	C0005682
27613550	1521	1531	recurrence	T046	C2825055
27613550	1535	1567	upper tract urothelial carcinoma	T191	C2145472
27613550	1568	1576	patients	T101	C0030705
27613550	1584	1592	positive	T033	C1514241
27613550	1593	1608	smoking history	T033	C1519384
27613550	1631	1638	history	T033	C1519384
27613550	1642	1655	bladder tumor	T191	C0005695
27613550	1674	1676	pH	T081	C0020283
27613550	1681	1686	urine	T031	C0042036
27613550	1687	1699	alkalization	T061	C1550103
27613550	1704	1711	prevent	T080	C2700409
27613550	1712	1719	bladder	T023	C0005682
27613550	1720	1730	recurrence	T046	C2825055